Strategic Partnerships Proteros biostructures collaborates with major pharma players and has a history of notable partnerships (Orion, Adrestia, Thermo Fisher). This points to opportunities for co-development deals, expanded outsourcing arrangements, and scientific collaboration where Proteros complements client R&D pipelines.

Comprehensive Discovery With an integrated platform spanning protein sciences, X-ray crystallography, Cryo-EM, biophysics, screening, and computational/medicinal chemistry, Proteros offers end-to-end services that can be pitched to clients seeking streamlined target-to-lead workflows and faster program timelines.

Elite Targeting The focus on technically challenging targets and Nobel Prize–winning structural biology heritage positions Proteros as a go-to partner for high-risk, high-reward programs, suggesting upsell potential in difficult targets where competitors may underperform.

Growth and Capacity Revenue is in the $10–25M range with ongoing expansion, indicating a growth-oriented partner open to larger engagements, multi-target programs, and longer-term contracts as their platform scales.

Global Reach Existing collaboration footprint with more than 250 pharmaceutical and biotech customers, including several of the world’s largest companies, implies a ready ecosystem for expanding enterprise-level deals, preferred vendor status, and referrals within a broad network.